Image Rhian Evans Ph.D., Scientist Rhian is a Scientist from Swansea University in Medical and Healthcare Studies and was featured in several collaborative publications. Rhian’s research-based background focused on tissue-based pathology in Multiple Sclerosis, primarily using immunohistochemical analysis and in vitro molecular techniques. She spent a short period conducting routine PCR testing for COVID-19 at the end of 2020. Published Pieces by Rhian Evans Tips & Tricks to Multiplexing: How to Choose Chromogen Colors for Multiplex and Detection Systems for Multiplex AssaysLS ArticlesLearn more about multiplexing and explore these educational videos and infographics to understand how to choose chromogen colors for multiplex, as well as the different detection systems available for multiplex assays. H&E Image Quality & Tissue-based ResearchArticles, LS ArticlesH&E is an important tool for disease research and drug development and is being increasingly combined with digital pathology technology. Image quality is important for slide digitization to ensure that interpretation is accurate. Take a look at some images here, produced by our digital pathology scanners. H&E Image Quality & Tissue-based ResearchArticles, LS ArticlesH&E is an important tool for disease research and drug development and is being increasingly combined with digital pathology technology. Image quality is important for slide digitization to ensure that interpretation is accurate. Take a look at some images here, produced by our digital pathology scanners. H&E Image Quality & Tissue-based ResearchArticles, LS ArticlesH&E is an important tool for disease research and drug development and is being increasingly combined with digital pathology technology. Image quality is important for slide digitization to ensure that interpretation is accurate. Take a look at some images here, produced by our digital pathology scanners. Cryosectioning 101 for Research Q&AArticoli, LS ArticlesIn the webinar Cryosectioning 101 for Research, John Stock provided a comprehensive guide on achieving better cryosectioning outcomes. John went on to answer customer questions at the end of the session, that have been compiled for your viewing here. Cryosectioning 101 for Research Q&AArticoli, LS ArticlesIn the webinar Cryosectioning 101 for Research, John Stock provided a comprehensive guide on achieving better cryosectioning outcomes. John went on to answer customer questions at the end of the session, that have been compiled for your viewing here. Cryosectioning 101 for Research Q&AArticoli, LS ArticlesIn the webinar Cryosectioning 101 for Research, John Stock provided a comprehensive guide on achieving better cryosectioning outcomes. John went on to answer customer questions at the end of the session, that have been compiled for your viewing here. Digital Pathology in Toxicological Pathology StudiesArticles, LS NewsletterDrug development is a timely and costly process, with the average cost of bringing a single new drug to market costing $1.3 billion, taking anywhere between 10-15 years to finalize complete all clinical trials. Preclinical studies are the vital first steps in research and development and is estimated to cost $7M over 73 months. Up to 35% of drugs are eliminated at phase I and II clinical trials due to toxicity. Digital Pathology in Toxicological Pathology StudiesArticles, LS NewsletterDrug development is a timely and costly process, with the average cost of bringing a single new drug to market costing $1.3 billion, taking anywhere between 10-15 years to finalize complete all clinical trials. Preclinical studies are the vital first steps in research and development and is estimated to cost $7M over 73 months. Up to 35% of drugs are eliminated at phase I and II clinical trials due to toxicity. Digital Pathology in Toxicological Pathology StudiesArticles, LS NewsletterDrug development is a timely and costly process, with the average cost of bringing a single new drug to market costing $1.3 billion, taking anywhere between 10-15 years to finalize complete all clinical trials. Preclinical studies are the vital first steps in research and development and is estimated to cost $7M over 73 months. Up to 35% of drugs are eliminated at phase I and II clinical trials due to toxicity. Pagination Current page 1 Page 2 Page 3 » Next